Developmental ORIgins of Healthy and Unhealthy AgeiNg: the Role of Maternal Obesity (DORIAN)

March 21, 2016 updated by: Pirjo Nuutila, Turku University Hospital

The prevalence of obesity in the developed world has increased markedly over the last 20 years. Considering the prevalence of obese and overweight adult subjects, and the fact that pregnancy itself induces a state of insulin resistance and inflammation, maternal obesity may be the most common health risk for the developing fetus. It is well established that what we eat has a major impact on our health. However, there is growing evidence to suggest that diet during pregnancy and lactation may be particularly important as not only does it influence the health of the mother, it may have a permanent effect on the health of her children and even her grandchildren. The concept that environmental factors, such as nutrition during early development, influence both our health span and lifespan has been termed the developmental origins of health and disease hypothesis.

The objective of the study are:

  • to compare subjects with frailty (condition developed with ageing) with controls and characterize the unhealthy aged condition with the measurements described below
  • to examine if signs of frailty can be reversed by lifestyle induced modifications (exercise training programme) of its primary components (IR, sarcopenia, psychological profile) in offspring of overweight/obese (OOM) vs lean mothers (OLM).

The study consists of 37 frail old subjects, age ≥ 65 sub-grouped in 17 OOM, and 20 OLM and 11 non frail controls. These subjects will be studied with positron emission tomography (PET), computed tomography (CT), magnetic resonance imaging (MRI) and spectroscopy (MRS) and ultra sounds (US). In addition functional MRI (fMRI) will be performed. Adipose tissue biopsies will be taken.

Subjects will undergo characterization of biohumoral markers, a 75 g oral glucose tolerance test, imaging biomarkers (PET/CT, US, fMRI-MRS), genetic biomarkers (DNA and telomere damage) and inflammatory biomarkers (macrophage infiltration) before and after the 4-month lifestyle intervention period (physical exercise). By PET/CT it will be measured tissue-specific IR in skeletal muscle, adipose tissue, liver, myocardium and targeted brain regions. MRS will be used to measure organ steatosis in the skeletal muscle and liver, MRI will be used to measure fat masses in abdominal areas, and fMRI will be performed to assess activation in brain regions regulating cognition and appetite/energy control. US will be used to assess cardiovascular markers (IMT, strain and function).

Study Overview

Study Type

Interventional

Enrollment (Actual)

48

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Helsinki, Finland, 00014
        • University of Helsinki, Department of General Practice and Primary Health Care
      • Turku, Finland, 20521
        • Turku PET Centre (Turku University Hospital)

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Subjects must be already participating the Helsinki Birth Cohort Study

Frailty Groups Inclusion Criteria:

  • (Frailty) with lowest half of adult grip strength (measured 2001-2004)
  • Group OM: (Offspring of Obese mothers) Highest quartile of maternal BMI
  • Group LM: (Offspring of Normal weight/Lean mothers) Lowest two quartiles of maternal BMI

Control group Inclusion Criteria:

  • (no Frailty) with highest half of adult grip strength (measured 2001-2004)
  • Offspring of normal weight mothers

Exclusion Criteria:

  • Subjects whose mothers were pre-eclamptic during pregnancy
  • Oral corticosteroid or Warfarin therapy
  • Recent myocardial infarction
  • Severe chronic disorder that can prevent to participate the intervention
  • Chronic atrial fibrillation and pacemaker
  • Cancer less than 5 years ago
  • Current smoking
  • Diabetes requiring insulin treatment or fasting glucose more than 7 mmol/l
  • Weight more than 170 kg and Waist circumference > 150 cm
  • Inner ear implants
  • Metal objects in body including metallic prostheses, artificial valve prostheses, surgical clips, braces, foreign fragments or tattoo

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Exercise Training - 17 offspring of OM
4 months exercise training, OM: Obese mothers
Three times a week, for four months.
No Intervention: 11 non-frail controls (9 LM)
Studied only at baseline
Experimental: Exercise Training - 20 offspring of LM
4 months exercise training, LM:Lean/Normal Mothers
Three times a week, for four months.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Baseline group comparison and Change from Baseline in Insulin-stimulated whole body and organ-specific glucose uptake at 4 months
Time Frame: At day 1 and after 4 months of intervention (for the 15 controls only at baseline)
Assessed via 18F-Fluorodeoxyglucose (FDG)-PET/CT+Clamp technique
At day 1 and after 4 months of intervention (for the 15 controls only at baseline)
Baseline group comparison and Change from Baseline in Epigenetic characterization of DNA samples (Telomere length, H2A.X phosphorilation, mtDNA deletion, p66) at 4 months
Time Frame: At day 1 and after 4 months of intervention (for the 15 controls only at baseline)
Telomere length, H2A.X phosphorilation, mtDNA deletion are measurements performed in Pisa, National Research Council p66 presence is measured in Rome, Istituto Superiore di Sanita'
At day 1 and after 4 months of intervention (for the 15 controls only at baseline)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Baseline group comparison and Change from Baseline in Fat masses and content via MRI and MRS at 4 months
Time Frame: At day 1 and after 4 months of intervention (for the 15 controls only at baseline)
Adipose tissue fat masses in different depots (subcutaneous, visceral, pericardial) Liver, skeletal muscle, vertebral fat content
At day 1 and after 4 months of intervention (for the 15 controls only at baseline)
Baseline group comparison and Change from Baseline in MRI brain anatomy and fMRI characterization of activation response to food stimuli of different brain regions at 4 months
Time Frame: At day 1 and after 4 months of intervention
MRI anatomy: White matter volume, Cortex thickness, Nerve tracks found with Diffusor Tension Imaging fMRI will be used to identify different brain regions activated by food stimuli while subjects perform three different task: watch the food, think of eating the food, control the urge to eat the food.
At day 1 and after 4 months of intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Pirjo Nuutila, MD PhD, Turku PET Centre (Turku University Hospital)

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

June 1, 2012

Primary Completion (Actual)

April 1, 2014

Study Completion (Actual)

June 1, 2015

Study Registration Dates

First Submitted

April 22, 2013

First Submitted That Met QC Criteria

August 26, 2013

First Posted (Estimate)

August 29, 2013

Study Record Updates

Last Update Posted (Estimate)

March 22, 2016

Last Update Submitted That Met QC Criteria

March 21, 2016

Last Verified

March 1, 2016

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Muscle Weakness

Clinical Trials on Exercise Training

3
Subscribe